Elevance Health Reports Second Quarter 2025 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall St set to gain on tech rebound, Middle East in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Axsome Therapeutics (AXSM) PT Raised to $380 at Jefferies
Elevance (ELV) PT Lowered to $350 at BofA Securities
July 17, 2025 12:10 PM EDTBofA Securities analyst Kevin Fischbeck lowered the price target on Elevance (NYSE: ELV) to $350.00 (from $420.00) while maintaining a Neutral rating.
The analyst comments "Despite a Q2 in-line with company expectations, ELV cut guidance by 13%, citing higher trend in exchanges... More
Elevance Health Inc. (ELV) Misses Q2 EPS by 23c, Beats on Revenue; Offers FY25 EPS Guidance
July 17, 2025 6:02 AM EDTElevance Health Inc. (NYSE: ELV) reported Q2 EPS of $8.84, $0.23 worse than the analyst estimate of $9.07. Revenue for the quarter came in at $49.4 billion versus the consensus estimate of $48.14 billion.
GUIDANCE:
Elevance Health Inc. sees FY2025 EPS of $30.00, versus the consensus of... More
